Apellis Pharmaceuticals Inc
NASDAQ: APLS · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-04-29
Apellis Pharmaceuticals Inc (APLS) Stock Valuation Analysis
Fair value estimate, historical valuation range, and quality signals for APLS.
Current price exceeds what fundamentals support. Risk/reward skewed unfavorably.
APLS historical valuation range
Where current P/E sits in APLS's own 5Y range.
APLS intrinsic value (DCF)
DCF-based fair value estimate vs current market price.
Intrinsic value calculated using discounted cash flow (DCF) model based on projected free cash flows, discount rate, and terminal growth assumptions. A positive margin of safety indicates the current price is below estimated fair value, providing a cushion against estimation error.
APLS valuation signals
Quick-read green flags, caution flags, and risks based on current metrics.
P/E Ratio — History
Current: 227.50x
P/S Ratio — History
Current: 5.22x
Is APLS overvalued in 2026?
Apellis Pharmaceuticals Inc (APLS) currently trades at $40.95 per share with a market capitalization of $5,242,471,000.00. Based on our multi-factor framework, the stock appears richly valued with a Smart Value Score of 27/100. This score blends growth quality, financial health, and price attractiveness into a single institutional-grade read.
The stock trades at a P/E ratio of 227.5x.
Our discounted cash flow model estimates APLS's intrinsic value at $193.03 per share, against the current market price of $40.95. This implies a margin of safety of +88.44%. A meaningful cushion exists against model error, making this a reasonable risk-adjusted entry.
The Piotroski F-Score of 5/9 puts financial quality in a middling range, neither a standout strength nor an obvious red flag.
Bottom line: APLS appears richly valued on our framework, with a Smart Value Score of 27/100. At current levels the risk/reward is skewed against the buyer. A materially lower price or significant operational improvement would be needed to change the picture.
Frequently asked questions
Is APLS overvalued in 2026?
Based on a Smart Value Score of 27/100, APLS appears overvalued. Current price exceeds what fundamentals currently justify.
What is APLS's fair value?
Our DCF model estimates APLS's intrinsic value at $193.03 per share, versus the current price of $40.95. This produces a margin of safety of +88.44%.
What P/E ratio does APLS trade at?
APLS trades at a P/E of 227.5x on trailing twelve-month earnings.
Is APLS a buy based on valuation?
WallStSmart does not issue buy or sell recommendations. Our Smart Value Score of 27/100 reflects the combined read on growth, quality, and price. The profile skews cautious. Consider waiting for a better price or clearer operational improvement.
How does APLS's valuation compare to its history?
Insufficient historical valuation data exists yet for a confident percentile read on APLS.
What is APLS's Smart Value Score?
APLS's Smart Value Score is 27/100. The Smart Value Score is a proprietary WallStSmart metric blending growth quality, financial health, and valuation attractiveness into a single 0-100 read. Scores above 75 are rare and indicate strong multi-factor alignment.